BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 28972073)

  • 21. Acquired expression of osteopontin selectively promotes enrichment of leukemia stem cells through AKT/mTOR/PTEN/β-catenin pathways in AML cells.
    Mohammadi S; Ghaffari SH; Shaiegan M; Zarif MN; Nikbakht M; Akbari Birgani S; Alimoghadam K; Ghavamzadeh A
    Life Sci; 2016 May; 152():190-8. PubMed ID: 27063991
    [TBL] [Abstract][Full Text] [Related]  

  • 22. BETP degradation simultaneously targets acute myelogenous leukemia stem cells and the microenvironment.
    Piya S; Mu H; Bhattacharya S; Lorenzi PL; Davis RE; McQueen T; Ruvolo V; Baran N; Wang Z; Qian Y; Crews CM; Konopleva M; Ishizawa J; You MJ; Kantarjian H; Andreeff M; Borthakur G
    J Clin Invest; 2019 May; 129(5):1878-1894. PubMed ID: 30829648
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Survivin is highly expressed in CD34(+)38(-) leukemic stem/progenitor cells and predicts poor clinical outcomes in AML.
    Carter BZ; Qiu Y; Huang X; Diao L; Zhang N; Coombes KR; Mak DH; Konopleva M; Cortes J; Kantarjian HM; Mills GB; Andreeff M; Kornblau SM
    Blood; 2012 Jul; 120(1):173-80. PubMed ID: 22645176
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Overexpression of IL-3Rα on CD34+CD38- stem cells defines leukemia-initiating cells in Fanconi anemia AML.
    Du W; Li XE; Sipple J; Pang Q
    Blood; 2011 Apr; 117(16):4243-52. PubMed ID: 21330473
    [TBL] [Abstract][Full Text] [Related]  

  • 25. CD96 is a leukemic stem cell-specific marker in human acute myeloid leukemia.
    Hosen N; Park CY; Tatsumi N; Oji Y; Sugiyama H; Gramatzki M; Krensky AM; Weissman IL
    Proc Natl Acad Sci U S A; 2007 Jun; 104(26):11008-13. PubMed ID: 17576927
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Live kinase B1 maintains CD34
    Wang H; Wang X; Xin N; Qi L; Liao A; Yang W; Liu Z; Zhao C
    Mol Cell Biochem; 2017 Oct; 434(1-2):25-32. PubMed ID: 28397012
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Characterization of Imatinib Resistant CML Leukemic Stem/Initiating Cells and Their Sensitivity to CBP/Catenin Antagonists.
    Zhao Y; Wu K; Wu Y; Melendez E; Smbatyan G; Massiello D; Kahn M
    Curr Mol Pharmacol; 2018; 11(2):113-121. PubMed ID: 28933312
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Acute Myeloid Leukemia Stem Cell Heterogeneity and Its Clinical Relevance.
    Karantanos T; Jones RJ
    Adv Exp Med Biol; 2019; 1139():153-169. PubMed ID: 31134500
    [TBL] [Abstract][Full Text] [Related]  

  • 29. CD93 Marks a Non-Quiescent Human Leukemia Stem Cell Population and Is Required for Development of MLL-Rearranged Acute Myeloid Leukemia.
    Iwasaki M; Liedtke M; Gentles AJ; Cleary ML
    Cell Stem Cell; 2015 Oct; 17(4):412-21. PubMed ID: 26387756
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Constitutive activation of Flt3 and STAT5A enhances self-renewal and alters differentiation of hematopoietic stem cells.
    Moore MA; Dorn DC; Schuringa JJ; Chung KY; Morrone G
    Exp Hematol; 2007 Apr; 35(4 Suppl 1):105-16. PubMed ID: 17379095
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Identification and separation of normal hematopoietic stem cells and leukemia stem cells from patients with acute myeloid leukemia.
    Hoang VT; Hoffmann I; Borowski K; Zepeda-Moreno A; Ran D; Buss EC; Wuchter P; Eckstein V; Ho AD
    Methods Mol Biol; 2013; 1035():217-30. PubMed ID: 23959995
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [In Vitro Identification and Characteristics of CD34
    Zhang YH; Yang L; Wang YZ; Kong Y; Zhu HH; Qin YZ
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Oct; 25(5):1289-1294. PubMed ID: 29070097
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The endosteum region keeps human leukemic stem cells alive.
    Lapidot T; Goichberg P; Lapid K; Avigdor A; Kollet O
    Cell Stem Cell; 2007 Nov; 1(5):483-4. PubMed ID: 18938742
    [No Abstract]   [Full Text] [Related]  

  • 34. Monoclonal antibody-mediated targeting of CD123, IL-3 receptor alpha chain, eliminates human acute myeloid leukemic stem cells.
    Jin L; Lee EM; Ramshaw HS; Busfield SJ; Peoppl AG; Wilkinson L; Guthridge MA; Thomas D; Barry EF; Boyd A; Gearing DP; Vairo G; Lopez AF; Dick JE; Lock RB
    Cell Stem Cell; 2009 Jul; 5(1):31-42. PubMed ID: 19570512
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Genetically distinct leukemic stem cells in human CD34- acute myeloid leukemia are arrested at a hemopoietic precursor-like stage.
    Quek L; Otto GW; Garnett C; Lhermitte L; Karamitros D; Stoilova B; Lau IJ; Doondeea J; Usukhbayar B; Kennedy A; Metzner M; Goardon N; Ivey A; Allen C; Gale R; Davies B; Sternberg A; Killick S; Hunter H; Cahalin P; Price A; Carr A; Griffiths M; Virgo P; Mackinnon S; Grimwade D; Freeman S; Russell N; Craddock C; Mead A; Peniket A; Porcher C; Vyas P
    J Exp Med; 2016 Jul; 213(8):1513-35. PubMed ID: 27377587
    [TBL] [Abstract][Full Text] [Related]  

  • 36. MRP1 protein expression in leukemic stem cells as a negative prognostic marker in acute myeloid leukemia patients.
    Paprocka M; Bielawska-Pohl A; Rossowska J; Krawczenko A; Duś D; Kiełbiński M; Haus O; Podolak-Dawidziak M; Kuliczkowski K
    Eur J Haematol; 2017 Nov; 99(5):415-422. PubMed ID: 28805931
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Leukemia-initiating cells from some acute myeloid leukemia patients with mutated nucleophosmin reside in the CD34(-) fraction.
    Taussig DC; Vargaftig J; Miraki-Moud F; Griessinger E; Sharrock K; Luke T; Lillington D; Oakervee H; Cavenagh J; Agrawal SG; Lister TA; Gribben JG; Bonnet D
    Blood; 2010 Mar; 115(10):1976-84. PubMed ID: 20053758
    [TBL] [Abstract][Full Text] [Related]  

  • 38. ELMO1 is upregulated in AML CD34+ stem/progenitor cells, mediates chemotaxis and predicts poor prognosis in normal karyotype AML.
    Capala ME; Vellenga E; Schuringa JJ
    PLoS One; 2014; 9(10):e111568. PubMed ID: 25360637
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Identification of a small subpopulation of candidate leukemia-initiating cells in the side population of patients with acute myeloid leukemia.
    Moshaver B; van Rhenen A; Kelder A; van der Pol M; Terwijn M; Bachas C; Westra AH; Ossenkoppele GJ; Zweegman S; Schuurhuis GJ
    Stem Cells; 2008 Dec; 26(12):3059-67. PubMed ID: 19096043
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prospective separation of normal and leukemic stem cells based on differential expression of TIM3, a human acute myeloid leukemia stem cell marker.
    Jan M; Chao MP; Cha AC; Alizadeh AA; Gentles AJ; Weissman IL; Majeti R
    Proc Natl Acad Sci U S A; 2011 Mar; 108(12):5009-14. PubMed ID: 21383193
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.